31st Oct 2013 13:36
LONDON (Alliance News) - e-Therapeutics said Thursday that it had started the Phase IIb trial of its ETS6103 treatment for major depressive disorder.
The trial is to evaluate the treatment as a second-line treatment for patients who have not responded adequately to first line therapy with a selective serotonin re-uptake inhibitor.
Shares in the drug development company were trading up 1.2% at 29.85 pence Thursday.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
ETX.L